How USP and DSP Optimization Can Help Reduce Inefficiencies and Cost?

Since only a small proportion of biotherapeutics that enter clinical trials make it to reach the market, companies tend to have a large pipeline of candidates, like monoclonal antibodies (mAbs) or gene therapy. This implies that there are many processes that need to be developed at the same time. In addition, pressure from healthcare providers is driving the need to reduce the manufacturing costs. Therefore, upstream and downstream optimization is necessary. The Bioprocessing of Biologics like m...
Read More

5 Biotech Companies Join Forces to Develop a Thermostable SARS-CoV-2 Delta Variant Vaccine

The continuous emergence of SARS-CoV-2 variants has highlighted the global need to immunize the population. For this reason, the STABVAC4COV project aims to develop a vaccine against the Delta variant of SARS-CoV-2 that is more stable than the current ones and, consequently, easier to distribute. mRNA technology will be used for its development. In parallel, the proyect will work on the development of compounds, especially enzymes involved in the RNA synthesis process in vitro. With this kno...
Read More

Different expression systems that 53Biologics use

The central dogma of biology is based on the sequence of DNA to RNA to Protein. To create a specific protein, DNA must initially be transcribed into mRNA, which is then translated into a polypeptide chain, forming the primary structure of the protein. Subsequently, the majority of proteins are modified via an array of post-translational modifications, including protein folding, formation of disulfide bridges, glycosylation, and acetylation. The process of synthesizing proteins from mRNA and addi...
Read More

Biopharmaceutical companies: 4 Factors to Consider for the selection of your Biologics CDMO Partner

In recent years, there has been a notable increase in the number of therapeutic molecules. This increase has led to a corresponding increase in the number of CDMOs like us. With so many CDMOs to choose from, it is crucial for biopharmaceutical companies to carefully consider their selection criteria.   Finding the Right Biologics CDMO Partner  To ensure that you select the right biologics CDMO partner for your project, it’s important to ask yourself: Will you be working with the CDMO...
Read More

Oligofastx project, development of RNA-based therapeutics

53Biologics participates in the OLIGOFASTX project. This project aims to create a comprehensive platform to facilitate and contribute to the accelerated development of oligonucleotide-based therapies in Spain. OLIGOFASTX is a multidisciplinary consortium led by Sylentis (PharmaMar Group) and in which other companies such as Nanovex Biotechnologies, ARTHEx Biotech, Aptus Data Labs, aptaTargets and Nostrum Biodiscovery participate in addition to 53Biologics. 53Biologics participates in th...
Read More

Which Are Better? Biologics or Small Molecule Drugs?

So to decide which is the best option in medicine and biopharma between biologics or small molecule drugs, we have to consider many factors. But let´s start from the beginning.  What Is a Small Molecule Drug?  Small molecule drugs are typically derived from natural compounds produced by plants, fungi and bacteria or are designed to imitate them. These drugs use biochemical processes to prevent or treat diseases. They are highly effective as allosteric modulators and enzyme inhibitors, and are...
Read More

Biologics CDMO: Why You Need One

The rapidly growing market for biologics has made contract biologics development and production corporations (CDMO) more essential. The complexity inherent in the development of biologics and their mass production for sale makes it impossible for biopharmaceutical and pharmaceutical companies to perform the process in-house. What Is a Biologics CDMO Company?  A contract biologics development and manufacturing company (CDMO) provides medical biologics development and manufacturing services for p...
Read More

Accelerating Biologics Manufacturing

In today’s pharmaceutical and biotechnology industry, the focus is on reducing development time and obtaining faster approval for high-quality therapies. However, biologics present unique and time-consuming challenges, such as cell line and analytical development, biological instability, scale-up and limited capacity, which can negatively impact time to market and financial results. Here are 5 steps to create a successful strategy that will help accelerate the time to a robust and reliable...
Read More

Why is Pichia Pastoris a good alternative for the production of recombinant proteins?

Pichia pastoris is a methylotrophic yeast belonging to the class Ascomycetes. Found in the 1960s, its main characteristic is to use methanol as a carbon and energy source. After years of study, P. pastoris has become a model organism for genetic study, being important in the field of biological and biotechnological research. Pichia pastoris is a yeast currently widely used as an expression system for the production of recombinant proteins, both for basic research and industrial purposes,...
Read More

What is the best known living being in the scientific field?

The best known organism in science is certainly a bacterium that lives in the human intestine. Invisible to the naked eye, Escherichia coli is largely responsible for the knowledge of some of the fundamentals of modern biology that have been recognized by several Nobel prizes.  These are the processes of bacterial genetic recombination, RNA transcription, DNA replication and gene regulation. In addition, in recent decades this bacterium has become another tool in the laboratory, especially...
Read More